Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B London

Showing results (161-170 of 310) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidyRochelle Bagatell, Pavlina Rumcheva, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology GroupW B London, R P Castleberry, K K Matthay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastomaMarcio H Malogolowkin, Howard Katzenstein, Mark D Krailo, et al.
Annals of Surgery|September 12, 2012
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group studyJed G Nuchtern, Wendy B London, Carol E Barnewolt, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
Pediatric Dermatology|August 15, 2019
Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort StudyEdward B Li, Johanna S Song, Jennifer T Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2011
Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG projectPaola Angelini, Wendy B London, Susan L Cohn, et al.
Journal of the National Cancer Institute|June 26, 2008
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomasTomoyuki Fujita, Jun Igarashi, Erin R Okawa, et al.
Pediatric Blood & Cancer|June 2, 2025
Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology GroupHetal Dholaria, Arlene Naranjo, Fan F Zhang, et al.
Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.
Pageof 31

Showing results (161-170 of 310) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidyRochelle Bagatell, Pavlina Rumcheva, Wendy B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology GroupW B London, R P Castleberry, K K Matthay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastomaMarcio H Malogolowkin, Howard Katzenstein, Mark D Krailo, et al.
Annals of Surgery|September 12, 2012
A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group studyJed G Nuchtern, Wendy B London, Carol E Barnewolt, et al.
Oncotarget|June 23, 2014
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1Jeyran Shahbazi, Christopher J Scarlett, Murray D Norris, et al.
Pediatric Dermatology|August 15, 2019
Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort StudyEdward B Li, Johanna S Song, Jennifer T Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2011
Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG projectPaola Angelini, Wendy B London, Susan L Cohn, et al.
Journal of the National Cancer Institute|June 26, 2008
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomasTomoyuki Fujita, Jun Igarashi, Erin R Okawa, et al.
Pediatric Blood & Cancer|June 2, 2025
Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology GroupHetal Dholaria, Arlene Naranjo, Fan F Zhang, et al.
Pediatric Blood & Cancer|July 22, 2014
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group projectHolly J Meany, Wendy B London, Peter F Ambros, et al.
Pageof 31